For research use only. Not for therapeutic Use.
MK-8876 is a HCV NS5B Site D Inhibitor.
| Catalog Number | I008079 |
| CAS Number | 1426960-33-9 |
| Synonyms | MK-8876; MK 8876; MK8876.;2-(4-Fluorophenyl)-5-(11-fluoro-6H-pyrido[2/’,3/’:5,6][1,3]oxazino[3,4-a]indol-2-yl)-N-methyl-6-[methyl(methylsulfonyl)amino]-3-benzofurancarboxamide |
| Molecular Formula | C32H24F2N4O5S |
| Purity | ≥95% |
| Target | HCV NS5B Site D Inhibitor |
| Solubility | Soluble in DMSO |
| Storage | 0 - 4 °C for short term, or -20 °C for long term |
| InChI | InChI=1S/C32H24F2N4O5S/c1-35-32(39)29-21-13-20(25(37(2)44(3,40)41)15-28(21)43-31(29)17-7-9-18(33)10-8-17)23-11-12-27-30(36-23)26-14-19-22(34)5-4-6-24(19)38(26)16-42-27/h4-15H,16H2,1-3H3,(H,35,39) |
| InChIKey | GOHCXBUFLQKEIO-UHFFFAOYSA-N |
| SMILES | O=C(C1=C(C2=CC=C(F)C=C2)OC3=CC(N(C)S(=O)(C)=O)=C(C4=CC=C5C(C(N6CO5)=CC7=C6C=CC=C7F)=N4)C=C13)NC |
| Reference | </br>Process Development of the HCV NS5B Site D Inhibitor MK-8876 Michael J. Williams†, Qinghao Chen*†, Lorenzo Codan§, Renee K. Dermenjian†, Spencer Dreher†, Andrew W. Gibson‡, Xianliang He∥, Yan Jin†, Stephen P. Keen‡, Alfred Y. Lee†, David R. Lieberman‡, Wei Lin∥, Guiquan Liu∥, Mark McLaughlin†, Mikhail Reibarkh†, Jeremy P. Scott‡, Sophie Strickfuss‡, Lushi Tan†, Richard J. Varsolona†, and Feng Wen∥ † Department of Process Research and Development, Merck Research Laboratories, Rahway, New Jersey 07065, United States ‡ Department of Process Chemistry, Merck Sharp & Dohme Ltd., Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom § Werthenstein BioPharma GmbH (MSD Switzerland), Industrie Nord 1, CH-6105 Schachen, Switzerland ∥ WuXi AppTec Co., Ltd., No. 1 Building, #288 FuTe ZhongLu, WaiGaoQiao Free Trade Zone, Shanghai 200131, China Org. Process Res. Dev., 2016, 20 (7), pp 1227–1238 DOI: 10.1021/acs.oprd.5b00405 Publication Date (Web): January 25, 2016 Copyright © 2016 American Chemical Society |
